CTMX Q2 2017 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$822M

Q2 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M+182.9% YoY

Gross Profit

$9M100.0% margin

Operating Income

-$25M-289.9% margin

Net Income

-$25M-288.1% margin

EPS (Diluted)

$-0.69

QoQ Revenue Growth

-24.9%

Cash Flow

Operating Cash Flow

$173M

Free Cash Flow

$173M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$352M

Total Liabilities

$300M

Stockholders' Equity

$52M

Cash & Equivalents

$273M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$3M	+182.9%
Gross Profit	$9M	$3M	+182.9%
Operating Income	-$25M	-$14M	-78.0%
Net Income	-$25M	-$14M	-77.9%